共找到 20 条结果
Voice-based screening offers a scalable and non-invasive way to assess neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), but their staging remains challenging due to the difficulty of integrating heterogeneous data. This paper presents NeurMLLM, an efficient multimodal generative framework for neurodegenerative disease staging. NeurMLLM first encodes the spectrograms and Mel-frequency cepstral coefficients of audio data with vision transformers and projects their representations into the embedding space of a large language model (LLM), where they are concatenated with transcript and demographic instruction tokens as a single unified sequence. The LLM is then instruction-tuned via Low-Rank Adaptation using task prompts to autoregressively predict a constrained label token, enabling a generative classification. By evaluating on the Bridge2AI-Voice dataset for fine-grained staging of AD and PD, we observe that NeurMLLM achieves strong performance, consistently outperforming classical machine learning methods and existing LLM-based approaches. The results show the high potential of multimodal LLMs in neurodegenerative disease staging, improving s
Recent advances in Artificial Intelligence (AI) and the exploration of noninvasive, objective biomarkers, such as speech signals, have encouraged the development of algorithms to support the early diagnosis of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). Voice changes in subjects suffering from ALS typically manifest as progressive dysarthria, which is a prominent neurodegenerative symptom because it affects patients as the disease progresses. Since voice signals are complex data, the development and use of advanced AI techniques are fundamental to extracting distinctive patterns from them. Validating AI algorithms for ALS diagnosis and monitoring using voice signals is challenging, particularly due to the lack of annotated reference datasets. In this work, we present the outcome of a collaboration between a multidisciplinary team of clinicians and Machine Learning experts to create both a clinically annotated validation dataset and the "Speech Analysis for Neurodegenerative Diseases" (SAND) challenge based on it. Specifically, by analyzing voice disorders, the SAND challenge provides an opportunity to develop, test, and evaluate AI models for the auto
Neurodegenerative disorders such as Alzheimer's disease exhibit highly organized patterns of regional brain vulnerability, yet the biological mechanisms underlying this spatial selectivity remain incompletely understood. Existing imaging-transcriptomic studies have largely relied on correlation-based analyses between gene expression and neuroimaging phenotypes, limiting their ability to model how molecular organization gives rise to neurodegeneration. Here, we introduce a cross-scale spatially-aware generative framework for modeling transcriptomic programs underlying cortical neurodegeneration. Regional transcriptomic profiles were derived from the Allen Human Brain Atlas using 910 landmark genes across 68 cortical regions. Neurodegenerative vulnerability maps were constructed from ADNI FreeSurfer cortical thickness measurements by computing regional cortical thinning differences between cognitively normal controls (NC = 926) and Alzheimer's disease subjects (AD = 426). A variational generative architecture was used to learn latent biological programs linking regional gene-expression organization to cortical degeneration while incorporating graph-based spatial smoothness regulariza
Accurately predicting the temporal evolution of clinical biomarkers is crucial for the early diagnosis and management of neurodegenerative diseases such as Alzheimer's disease. However, this relies on longitudinal data to capture biomarker changes over time, which is often sparse and irregular due to the high cost, labor-intensive nature, and patient burden. To address these challenges, we propose ENC-ODE, an Event-level Neurodegenerative modeling in Continuous time with neural Ordinary Differential Equations. ENC-ODE predicts future biomarker evolution by modeling clinical events through diagnosis-conditioned continuous dynamics. A target-conditioned attention mechanism weights and aggregates event-level predictions for the target time and modality without history compression. Extensive experiments on Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset demonstrate that ENC-ODE outperforms representative sequence models while offering a scalable and neuroscientifically grounded solution for clinical support. The code is available at https://github.com/JardinDelSol/enc-ode.
INTRODUCTION: Accurate MRI-based identification of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related dementias remains challenging because disease-related structural changes are often subtle and heterogeneous. We developed NeuroBridge, a clinically guided multi-task MRI framework for neurodegenerative disease diagnosis. METHODS: NeuroBridge integrates large-scale self-supervised MRI pretraining with hippocampal segmentation, hippocampal atrophy classification, and reconstruction objectives, followed by gated fusion fine-tuning. Performance was evaluated across ADNI and OASIS cohorts, including cross-cohort transfer, probability-based analysis, and opportunistic screening. RESULTS: NeuroBridge achieved the highest performance across evaluated classification tasks, reaching 88.17% accuracy for AD versus cognitively normal controls in ADNI and 82.78% in OASIS. The largest gains occurred in MCI-related and mixed-diagnosis settings. The framework demonstrated strong cross-cohort generalization, systematic associations between predicted-class probability and accuracy, and the feasibility of probability-based opportunistic screening. DISCUSSION: Clinically guided mult
Identifying preclinical biomarkers of neurodegenerative diseases remains a major challenge in aging research. In this study, we demonstrate that frequent "Don't know/can't remember" (DK) responses, often treated as missing data in touchscreen questionnaires, serve as a novel digital behavioral biomarker of early cognitive vulnerability and neurodegenerative disease risk. Using data from 502,234 UK Biobank participants, we stratified individuals based on DK response frequency (0-1, 2-4, 5-7, >7) and observed a robust, dose-dependent association with an increased risk of Alzheimer's disease (HR = 1.64, 95% CI: 1.26-2.14) and vascular dementia (HR = 1.93, 95% CI: 1.37-2.72), independent of established risk factors. As DK response frequency increased, participants exhibited higher BMI, reduced physical activity, higher smoking rates, and a higher prevalence of chronic diseases, particularly hypertension, diabetes, and depression. Further analysis revealed a dose-dependent relationship between DK response frequency and the risk of Alzheimer's disease and vascular dementia, with high DK responders showing early neurodegenerative changes, marked by elevated levels of Abeta40, Abeta42,
Early detection of neurodegenerative diseases such as Alzheimer's Disease (AD) and Frontotemporal Dementia (FTD) is essential for reducing the risk of progression to severe disease stages. As AD and FTD propagate along white-matter regions in a global, graph-dependent manner, graph-based neural networks are well suited to capture these patterns. Hence, we introduce ARMARecon, a unified graph learning framework that integrates Autoregressive Moving Average (ARMA) graph filtering with a reconstruction-driven objective to enhance feature representation and improve classification accuracy. ARMARecon effectively models both local and global connectivity by leveraging 20-bin Fractional Anisotropy (FA) histogram features extracted from white-matter regions, while mitigating over-smoothing. Overall, ARMARecon achieves superior performance compared to state-of-the-art methods on the multi-site dMRI datasets ADNI and NIFD.
Understanding and predicting the progression of neurodegenerative diseases remains a major challenge in medical AI, with significant implications for early diagnosis, disease monitoring, and treatment planning. However, most available longitudinal neuroimaging datasets are temporally sparse with a few follow-up scans per subject. This scarcity of temporal data limits our ability to model and accurately capture the continuous anatomical changes related to disease progression in individual subjects. To address this problem, we propose a novel 4D (3DxT) diffusion-based generative framework that effectively models and synthesizes longitudinal brain anatomy over time, conditioned on available clinical variables such as health status, age, sex, and other relevant factors. Moreover, while most current approaches focus on manipulating image intensity or texture, our method explicitly learns the data distribution of topology-preserving spatiotemporal deformations to effectively capture the geometric changes of brain structures over time. This design enables the realistic generation of future anatomical states and the reconstruction of anatomically consistent disease trajectories, providing
Forecasting the progression of neurodegenerative diseases, such as Parkinson's disease, is essential for effective long-term planning and personalized therapeutic intervention. Existing systems typically produce scalar clinical scores that ignore the rich structure of longitudinal neuroimaging, while traditional generative approaches suffer from a loss of anatomical details and blurring subtle progression patterns. To address this, we introduce a novel treatment-conditioned diffusion framework that predicts high-fidelity future brain states by conditioning the generative process on patients' screening DaTscan images and levodopa equivalent daily dose over one year. The pipeline uses a Transformer-based encoder to represent non-linear, time-dependent pharmacological dynamics and optimizes generation through a multi-weight region-of-interest mask that focuses on biologically critical areas. Experimental evaluation shows that our framework maintains sharp anatomical boundaries and significantly improves clinical fidelity relative to the baseline, achieving 14.0% lower MSE, 7.2% lower MAE, and 4.9% higher SSIM.
The differential diagnosis of neurodegenerative diseases, characterized by overlapping symptoms, may be challenging. Brain imaging coupled with artificial intelligence has been previously proposed for diagnostic support, but most of these methods have been trained to discriminate only isolated diseases from controls. Here, we develop a novel machine learning framework, named lifespan tree of brain anatomy, dedicated to the differential diagnosis between multiple diseases simultaneously. It integrates the modeling of volume changes for 124 brain structures during the lifespan with non-linear dimensionality reduction and synthetic sampling techniques to create easily interpretable representations of brain anatomy over the course of disease progression. As clinically relevant proof-of-concept applications, we constructed a cognitive lifespan tree of brain anatomy for the differential diagnosis of six causes of neurodegenerative dementia and a motor lifespan tree of brain anatomy for the differential diagnosis of four causes of parkinsonism using 37594 MRI as a training dataset. This original approach enhanced significantly the efficiency of differential diagnosis in the external valid
Voice biomarkers--human-generated acoustic signals such as speech, coughing, and breathing--are promising tools for scalable, non-invasive detection and monitoring of mental health and neurodegenerative diseases. Yet, their clinical adoption remains constrained by inconsistent quality and limited usability of publicly available datasets. To address this gap, we present the first systematic FAIR (Findable, Accessible, Interoperable, Reusable) evaluation of 27 publicly available voice biomarker datasets focused on these disease areas. Using the FAIR Data Maturity Model and a structured, priority-weighted scoring method, we assessed FAIRness at subprinciple, principle, and composite levels. Our analysis revealed consistently high Findability but substantial variability and weaknesses in Accessibility, Interoperability, and Reusability. Mental health datasets exhibited greater variability in FAIR scores, while neurodegenerative datasets were slightly more consistent. Repository choice also significantly influenced FAIRness scores. To enhance dataset quality and clinical utility, we recommend adopting structured, domain-specific metadata standards, prioritizing FAIR-compliant repositori
A central challenge in modeling neurodegenerative diseases is connecting cellular-level mechanisms to tissue-level pathology, in particular to determine whether pathology is driven primarily by cell-autonomous triggers or by propagation from cells that are already in a pathological, runaway aggregation state. To bridge this gap, we here develop a bottom-up physical model that explicitly incorporates these two fundamental cell-level drivers of protein aggregation dynamics. We show that our model naturally explains the characteristic long, slow development of pathology followed by a rapid acceleration, a hallmark of many neurodegenerative diseases. Furthermore, the model reveals the existence of a critical switch point at which the system's dynamics transition from being dominated by slow, spontaneous formation of diseased cells to being driven by fast propagation. This framework provides a robust physical foundation for interpreting pathological data and offers a method to predict which class of therapeutic strategies is best matched to the underlying drivers of a specific disease.
Parkinson's disease (PD) and Alzheimer's disease (AD) are the two most prevalent and incurable neurodegenerative diseases (NDs) worldwide, for which early diagnosis is critical to delay their progression. However, the high dimensionality of multi-metric data with diverse structural forms, the heterogeneity of neuroimaging and phenotypic data, and class imbalance collectively pose significant challenges to early ND diagnosis. To address these challenges, we propose a dynamically weighted dual graph attention network (DW-DGAT) that integrates: (1) a general-purpose data fusion strategy to merge three structural forms of multi-metric data; (2) a dual graph attention architecture based on brain regions and inter-sample relationships to extract both micro- and macro-level features; and (3) a class weight generation mechanism combined with two stable and effective loss functions to mitigate class imbalance. Rigorous experiments, based on the Parkinson Progression Marker Initiative (PPMI) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies, demonstrate the state-of-the-art performance of our approach.
Advancements in spoken language technologies for neurodegenerative speech disorders are crucial for meeting both clinical and technological needs. This overview paper is vital for advancing the field, as it presents a comprehensive review of state-of-the-art methods in pathological speech detection, automatic speech recognition, pathological speech intelligibility enhancement, intelligibility and severity assessment, and data augmentation approaches for pathological speech. It also highlights key challenges, such as ensuring robustness, privacy, and interpretability. The paper concludes by exploring promising future directions, including the adoption of multimodal approaches and the integration of large language models to further advance speech technologies for neurodegenerative speech disorders.
Mechanistic models of progressive neurodegeneration offer great potential utility for clinical use and novel treatment development. Toward this end, several connectome-informed models of neuroimaging biomarkers have been proposed. However, these models typically do not scale well beyond a small number of biomarkers due to heterogeneity in individual disease trajectories and a large number of parameters. To address this, we introduce the Connectome-based Monotonic Inference of Neurodegenerative Dynamics (COMIND). The model combines concepts from diffusion and logistic models with structural brain connectivity. This guarantees monotonic disease trajectories while maintaining a limited number of parameters to improve scalability. We evaluate our model on simulated data as well as on the Parkinson's Progressive Markers Initiative (PPMI) data. Our model generalizes to anatomical imaging representations from a standard brain atlas without the need to reduce biomarker number.
Deep learning has shown significant potential in diagnosing neurodegenerative diseases from MRI data. However, most existing methods rely heavily on large volumes of labeled data and often yield representations that lack interpretability. To address both challenges, we propose a novel self-supervised cross-encoder framework that leverages the temporal continuity in longitudinal MRI scans for supervision. This framework disentangles learned representations into two components: a static representation, constrained by contrastive learning, which captures stable anatomical features; and a dynamic representation, guided by input-gradient regularization, which reflects temporal changes and can be effectively fine-tuned for downstream classification tasks. Experimental results on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset demonstrate that our method achieves superior classification accuracy and improved interpretability. Furthermore, the learned representations exhibit strong zero-shot generalization on the Open Access Series of Imaging Studies (OASIS) dataset and cross-task generalization on the Parkinson Progression Marker Initiative (PPMI) dataset. The code for the
This work presents a structure-preserving, high-order, unconditionally stable numerical method for approximating the solution to the Fisher-Kolmogorov equation on polytopic meshes, with a particular focus on its application in simulating misfolded protein spreading in neurodegenerative diseases. The model problem is reformulated using an entropy variable to guarantee solution positivity, boundedness, and satisfaction of a discrete entropy-stability inequality at the numerical level. The scheme combines a local discontinuous Galerkin method on polytopal meshes for the space discretization with a $ν$-step backward differentiation formula for the time integration. Implementation details are discussed, including a detailed derivation of the linear systems arising from Newton's iteration. The accuracy and robustness of the proposed method are demonstrated through extensive numerical tests. Finally, the method's practical performance is demonstrated through simulations of $α$-synuclein propagation in a two-dimensional brain geometry segmented from MRI data, providing a relevant computational framework for modeling synucleopathies (such as Parkinson's disease) and, more generally, neurode
The differential diagnosis of neurodegenerative dementias is a challenging clinical task, mainly because of the overlap in symptom presentation and the similarity of patterns observed in structural neuroimaging. To improve diagnostic efficiency and accuracy, deep learning-based methods such as Convolutional Neural Networks and Vision Transformers have been proposed for the automatic classification of brain MRIs. However, despite their strong predictive performance, these models find limited clinical utility due to their opaque decision making. In this work, we propose a framework that integrates two core components to enhance diagnostic transparency. First, we introduce a modular pipeline for converting 3D T1-weighted brain MRIs into textual radiology reports. Second, we explore the potential of modern Large Language Models (LLMs) to assist clinicians in the differential diagnosis between Frontotemporal dementia subtypes, Alzheimer's disease, and normal aging based on the generated reports. To bridge the gap between predictive accuracy and explainability, we employ reinforcement learning to incentivize diagnostic reasoning in LLMs. Without requiring supervised reasoning traces or d
Brain age is the estimate of biological age derived from neuroimaging datasets using machine learning algorithms. Increasing \textit{brain age gap} characterized by an elevated brain age relative to the chronological age can reflect increased vulnerability to neurodegeneration and cognitive decline. Hence, brain age gap is a promising biomarker for monitoring brain health. However, black-box machine learning approaches to brain age gap prediction have limited practical utility. Recent studies on coVariance neural networks (VNN) have proposed a relatively transparent deep learning pipeline for neuroimaging data analyses, which possesses two key features: (i) inherent \textit{anatomically interpretablity} of derived biomarkers; and (ii) a methodologically interpretable perspective based on \textit{linkage with eigenvectors of anatomic covariance matrix}. In this paper, we apply the VNN-based approach to study brain age gap using cortical thickness features for various prevalent neurodegenerative conditions. Our results reveal distinct anatomic patterns for brain age gap in Alzheimer's disease, frontotemporal dementia, and atypical Parkinsonian disorders. Furthermore, we demonstrate t
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid-beta (A$β$) and phosphorylated tau (p-tau) proteins, leading to cognitive decline measured by the Alzheimer's Disease Assessment Scale (ADAS) score. In this study, we develop and analyze a system of ordinary differential equation models to describe the interactions between A$β$, p-tau, and ADAS score, providing a mechanistic understanding of disease progression. To ensure accurate model calibration, we employ Bayesian inference and Physics-Informed Neural Networks (PINNs) for parameter estimation based on Alzheimer's Disease Neuroimaging Initiative data. The data-driven Bayesian approach enables uncertainty quantification, improving confidence in model predictions, while the PINN framework leverages neural networks to capture complex dynamics directly from data. Furthermore, we implement an optimal control strategy to assess the efficacy of an anti-tau therapeutic intervention aimed at reducing p-tau levels and mitigating cognitive decline. Our data-driven solutions indicate that while optimal drug administration effectively decreases p-tau concentration, its impact on cogn